April 2010
Volume 51, Issue 13
ARVO Annual Meeting Abstract  |   April 2010
Suprachoroidal Drug Delivery for the Treatment of Advanced, Exudative Age-Related Macular Degeneration
Author Affiliations & Notes
  • S. Rizzo
    UO Chirurgia Oftalmica, Azienda Ospedaliero-Univ Pisana, Pisa, Italy
  • A. J. Augustin
    Ophthalmology, Klinikum Karlsruhe, Karlsruhe, Germany
  • M. Tetz
    Ophthalmological Department, Berlin, Germany
  • F. Genovesi-Ebert
    UO Chirurgia Oftalmica, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy
  • E. Di Bartolo
    UO Chirurgia Oftalmica, Azienda Ospedaliero-Univ Pisana, Pisa, Italy
  • Footnotes
    Commercial Relationships  S. Rizzo, None; A.J. Augustin, None; M. Tetz, None; F. Genovesi-Ebert, None; E. Di Bartolo, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 1256. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      S. Rizzo, A. J. Augustin, M. Tetz, F. Genovesi-Ebert, E. Di Bartolo; Suprachoroidal Drug Delivery for the Treatment of Advanced, Exudative Age-Related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2010;51(13):1256.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : Interim European multi-center clinical study results of suprachoroidal drug delivery with the use of a microcatheter for the treatment of advanced, exudative age-related macular degeneration (AMD).

Methods: : prospective study, 3 study centers (Pisa, Karlsruhe, Berlin).Inclusion criteria: AMD patients who have failed multiple conventional treatments (Lucentis®, Avastin®, PDT), with lesion size ≥ 4 Disk Area and Visual Acuity (VA) 20/400 to 20/40.Patients (pts) underwent single combination treatment: 1.25 mg Avastin + 4 mg Triamcinolone administered to macular region of suprachoroidal space through a microcatheter (iTRACKTM 400, iScience Interventional Corporation) introduced performing a 2-3 mm dissection at the pars plana and advanced posteriorly while visualizing the illuminated tip beneath the retina through the operating microscope. Patients follow-up was scheduled for 1 3,6 months post-surgery. Study parameters at 12 months were LogMAR VA, fluorescein angiography (FA), OCT and surgical complications

Results: : 21 pts were enrolled to date, no surgical complications have been observed. At baseline (21 pts) mean (m) LogMAR VA was 0.98 (SD 0.34), m. macular thickness on the OCT was 407 (SD 230). At 6 months (10 pts) m LogMAR VA was 0.97 (SD 0.28) ,m. macular thickness was 408 (SD 296). 29% of eyes improved more than 2 lines.Data at each follow-up were shown in table 1

Conclusions: : Suprachoroidal drug administration directly adjacent to the choroid in the submacular region may be a potential treatment for advanced AMD. Administering therapeutic agents through the suprachoroidal space may be desirable to allow for direct drug exposure to the choroid, potentially increasing choroidal drug levels.  

Keywords: age-related macular degeneration • vitreoretinal surgery • macula/fovea 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.